Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis

被引:23
作者
Sjostrom, Susanne [1 ]
Kallner, Helena Kopp [1 ,2 ]
Simeonova, Emilia [3 ]
Madestam, Andreas [4 ]
Gemzell-Danielsson, Kristina [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Div Obstet & Gynecol, Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Sci, Danderyds Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
[3] Johns Hopkins Univ, Carey Sch Business, Baltimore, MD USA
[4] Stockholm Univ, Dept Econ, Stockholm, Sweden
来源
PLOS ONE | 2016年 / 11卷 / 06期
基金
瑞典研究理事会;
关键词
ACTING REVERSIBLE CONTRACEPTION; UNINTENDED PREGNANCY; UNITED-STATES; POSTABORTION CONTRACEPTION; SAFE ABORTION; CARE; CHOICE; COHORT; TRIAL;
D O I
10.1371/journal.pone.0158645
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective The objective of the present study is to calculate the cost-effectiveness of early medical abortion performed by nurse-midwifes in comparison to physicians in a high resource setting where ultrasound dating is part of the protocol. Non-physician health care professionals have previously been shown to provide medical abortion as effectively and safely as physicians, but the cost-effectiveness of such task shifting remains to be established. Study design A cost effectiveness analysis was conducted based on data from a previously published randomized-controlled equivalence study including 1180 healthy women randomized to the standard procedure, early medical abortion provided by physicians, or the intervention, provision by nurse-midwifes. A 1.6% risk difference for efficacy defined as complete abortion without surgical interventions in favor of midwife provision was established which means that for every 100 procedures, the intervention treatment resulted in 1.6 fewer incomplete abortions needing surgical intervention than the standard treatment. The average direct and indirect costs and the incremental cost-effectiveness ratio (ICER) were calculated. The study was conducted at a university hospital in Stockholm, Sweden. Results The average direct costs per procedure were EUR 45 for the intervention compared to EUR 58.3 for the standard procedure. Both the cost and the efficacy of the intervention were superior to the standard treatment resulting in a negative ICER at EUR -831 based on direct costs and EUR -1769 considering total costs per surgical intervention avoided. Conclusion Early medical abortion provided by nurse-midwives is more cost-effective than provision by physicians. This evidence provides clinicians and decision makers with an important tool that may influence policy and clinical practice and eventually increase numbers of abortion providers and reduce one barrier to women's access to safe abortion.
引用
收藏
页数:9
相关论文
共 44 条
  • [31] A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
    Zindel, Sonja
    Stock, Stephanie
    Mueller, Dirk
    Stollenwerk, Bjoern
    [J]. BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [32] Cost-Effectiveness analysis of the surgical management of fractures in Malawi: An economic evaluation of a high and low-income country surgical collaboration
    Agwu, Chidera
    Purcell, Laura N.
    Gallaher, Jared
    Young, Sven
    Banza, Leonard
    Mansfield, Alyssa J.
    Charles, Anthony
    [J]. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2021, 52 (04): : 767 - 773
  • [33] Cost-Effectiveness Analysis of Consolidation With Brentuximab Vedotin for High-Risk Hodgkin Lymphoma After Autologous Stem Cell Transplantation
    Hui, Lucy
    von Keudell, Gottfried
    Wang, Rong
    Zeidan, Amer M.
    Gore, Steven D.
    Ma, Xiaomei
    Davidoff, Amy J.
    Huntington, Scott F.
    [J]. CANCER, 2017, 123 (19) : 3763 - 3771
  • [34] Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis
    Jiao, Boshen
    Basu, Anirban
    [J]. VALUE IN HEALTH, 2021, 24 (07) : 957 - 965
  • [35] Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China
    Levin, Carol E.
    Sellors, John
    Shi, Ju-Fang
    Ma, Li
    Qiao, You-lin
    Ortendahl, Jesse
    O'Shea, Meredith K. H.
    Goldie, Sue J.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (06) : 1404 - 1411
  • [36] Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis
    Wateska, Angela R.
    Nowalk, Mary Patricia
    Zimmerman, Richard K.
    Smith, Kenneth J.
    Lin, Chyongchiou J.
    [J]. BMC INFECTIOUS DISEASES, 2018, 18
  • [37] Cost-effectiveness analysis of comprehensive intervention programs to control blood glucose in overweight and obese type 2 diabetes mellitus patients based on a real-world setting: Markov modeling
    Wang, Hui
    Wang, Mengyang
    Wang, Jiao
    Liu, Hongwei
    Lu, Rui
    Duan, Tongqing
    Gong, Xiaowen
    Feng, Siyuan
    Cui, Zhuang
    Liu, Yuanyuan
    Li, Changping
    Ma, Jun
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (22)
  • [38] Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis
    Ryckman, Theresa
    Weiser, Jeff
    Gombe, Makaita
    Turner, Karin
    Soni, Priyanka
    Tarlton, Dessislava
    Mazhidova, Nargiza
    Churchyard, Gavin
    Chaisson, Richard E.
    Dowdy, David W.
    [J]. LANCET GLOBAL HEALTH, 2023, 11 (08): : E1205 - E1216
  • [39] The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
    Ma, Yue
    Zhou, Jiting
    Ye, Yuxin
    Wang, Xintian
    Ma, Aixia
    Li, Hongchao
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
    Yang, Han
    Li, Nan
    Zhou, Youlian
    Xiao, Zhilan
    Tian, Haoming
    Hu, Ming
    Li, Sheyu
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 157 - 165